— Catalyst Pharmaceutical (NASDAQ: CPRX) reported third quarter 2019 earnings of $0.13 per share, vs. $0.11 per share expected.
— Net product revenue came in at $30.9 million, vs. $33.2 million expected.
— Expects full year 2019 revenues of approx. $100 million. Revenues in 2020 projected to be in the range of $135 million to $155 million.
— CPRX shares fell 5.2% immediately following the announcement.
Most Popular
Kroger (KR) looks set to start 2023 with new vigor. Is the stock a buy?
The retail environment has witnessed many changes in customers’ shopping behavior lately, especially after the COVID outbreak. With inflation putting pressure on personal finances, there appears to be a new
Dollar General (DG): Five takeaways from the discount store’s Q3 earnings report
Shares of Dollar General Corporation (NYSE: DG) were up over 2% on Friday, a day after the company delivered mixed results for the third quarter of 2022 and lowered its
Salesforce stock hit by weak guidance, co-CEO’s exit. What next?
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected
